about
Combinatorial drug design targeting multiple cancer signaling networks controlled by mitochondrial Hsp90A multiscale approach to characterize the early aggregation steps of the amyloid-forming peptide GNNQQNY from the yeast prion sup-35Investigating the dynamic aspects of drug-protein recognition through a combination of MD and NMR analyses: implications for the development of protein-protein interaction inhibitorsDNA Polymerase Conformational Dynamics and the Role of Fidelity-Conferring Residues: Insights from Computational SimulationsMethionine sulfoxides on prion protein Helix-3 switch on the alpha-fold destabilization required for conversion.Dynamic diagnosis of familial prion diseases supports the β2-α2 loop as a universal interference target.The five-to-six-coordination transition of ferric human serum heme-albumin is allosterically-modulated by ibuprofen and warfarin: a combined XAS and MD studyCombined in silico and experimental approach for drug design: the binding mode of peptidic and non-peptidic inhibitors to hsp90 N-terminal domain.Folding and mis-folding of peptides and proteins: insights from molecular simulations.Novel PARP-1 Inhibitor Scaffolds Disclosed by a Dynamic Structure-Based Pharmacophore Approach.Molecular dynamics simulations of proteins and peptides: from folding to drug design.Molecular simulations of peptides: a useful tool for the development of new drugs and for the study of molecular recognition.A dynamic perspective on the molecular recognition of chitooligosaccharide ligands by hevein domains.Antileukemic activity of shepherdin and molecular diversity of hsp90 inhibitors.Rational design of shepherdin, a novel anticancer agent.Investigating the mechanism of peptide aggregation: insights from mixed monte carlo-molecular dynamics simulations.Crystal Structure of the DFNKF Segment of Human Calcitonin Unveils Aromatic Interactions between Phenylalanines.A Hamiltonian replica exchange molecular dynamics (MD) method for the study of folding, based on the analysis of the stabilization determinants of proteins.Pharmacological enhancement of α-glucosidase by the allosteric chaperone N-acetylcysteine.The structural intolerance of the PrP alpha-fold for polar substitution of the helix-3 methionines.Synthesis, structure and conformation of partially-modified retro- and retro-inverso psi[NHCH(CF3)]Gly peptides.A protease-resistant Escherichia coli asparaginase with outstanding stability and enhanced anti-leukaemic activity in vitro.Computational studies of the structure, dynamics and native content of amyloid-like fibrils of ribonuclease ASmall-Molecule Targeting of Heat Shock Protein 90 Chaperone Function: Rational Identification of a New Anticancer LeadHow the Ligand-Induced Reorganization of Protein Internal Energies Is Coupled to Conformational EventsMechanisms of Metabolite Amyloid Formation: Computational Studies for Drug Design against Metabolic DisordersEffects of water miscible organic solvents on the activity and conformation of the Baeyer-Villiger monooxygenases from Thermobifida fusca and Acinetobacter calcoaceticus: a comparative study
P50
Q24647585-3A9C7371-63D0-4755-AFBA-BBF05CE75CB7Q28478191-4EB1796E-BD47-44B4-8558-B98F5680CDD7Q28539120-80A8C44D-64AC-4D1E-B795-664FE74992C7Q28833304-F6C7CFD1-E712-4748-AEC6-D68663F4E97DQ33403195-F66362A3-8D0E-4D9D-BF3E-7F0C468D5D24Q33892707-C91F61FE-0EFE-45E5-B461-0B04C5640FC1Q34083630-47B02BCB-F23E-49E3-A6C3-CBD13B9218F5Q34192823-DA39CAFD-85A5-4528-AEA0-E1BC1AD82F37Q36107285-0DE10DDD-AE6F-4C01-B1C1-2434ADB8DE00Q36259861-17DF1374-0C21-4CE6-BF96-44A820F7364BQ37130886-43AAA486-65B7-4014-9466-5C647F0EC8EBQ37569734-1E6C69AC-06F1-4CE9-80AC-4511DC8E0986Q38329078-B315D290-E7D8-485C-8220-894C83848581Q40249025-7288F29A-B9B0-49C9-88EB-357712102B4DQ40422406-FCC3E7A8-EC75-4FE3-BFDB-AB658999A4EEQ40799501-7910F978-7570-42BB-863A-4026F81033F8Q41540882-A4FD6C07-5192-42D7-B5DB-D1B4108BC597Q41903561-95A3EDA6-C9B6-4D04-A328-CAD98CBE5795Q41912890-5A4F56DB-5B7C-4A2F-8FCA-E6086180962DQ43068298-9E0E3D34-6336-40D9-9359-CAD2D9C484A6Q44591926-209DEAEF-ADB9-4A5B-B76A-C19E4FF53862Q44619167-06DFE532-A75F-473E-BB8C-1FAE45F8F74DQ57794928-F708ADEB-3578-431C-85B0-A01B3FEAF49AQ57795122-8AC792BC-8346-4F1E-AB0B-720F234E86BCQ58327274-13707A4B-4D66-465C-A826-AD9A3BBAEA8EQ62630866-54708E6E-8C03-44E1-BC64-5CDACFFE3DC4Q85181951-9ED6C456-BDE8-4897-8126-290E84C62F32
P50
description
researcher, ORCID id # 0000-0003-3304-6104
@en
wetenschapper
@nl
name
Massimiliano Meli
@ast
Massimiliano Meli
@en
Massimiliano Meli
@es
Massimiliano Meli
@nl
type
label
Massimiliano Meli
@ast
Massimiliano Meli
@en
Massimiliano Meli
@es
Massimiliano Meli
@nl
prefLabel
Massimiliano Meli
@ast
Massimiliano Meli
@en
Massimiliano Meli
@es
Massimiliano Meli
@nl
P106
P21
P31
P496
0000-0003-3304-6104